Allergy

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, March 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Allergy, Investigational New Drug, PD, Research, YTE, Hereditary angioedema, Investment, Atopic dermatitis, Richard Driehaus, Safety, OX40, HAE, Therapy, Pharmacokinetics, Patient, Pharmaceutical industry

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • The trial is evaluating safety and tolerability, changes in HAE attack rate, pharmacokinetics (PK), pharmacodynamics (PD), and quality-of-life assessments.
  • Pending proof-of-concept results from the ALPHA-STAR trial, Astria expects to progress directly to a pivotal Phase 3 program which is anticipated to initiate in the first quarter of 2025.
  • Cash Position: As of December 31, 2023, Astria had cash, cash equivalents and short-term investments of $246.5 million, compared to $188.8 million as of September 30, 2023.

AI-Powered, Plant-Based Dog Food Brand PawCo Raises $2M to Scale Its Operations

Retrieved on: 
Thursday, February 29, 2024
Veterinary, Pets, Health, Artificial Intelligence, Technology, Food, Beverage, Consumer, Retail, Pet, Cancer, Dicarboxylic acid, AI, Impossible Foods, Marketing, Mineral, Vitamin, Growth, Dog, Meat, Allergy, Research, Environment

With this funding, PawCo will scale its operations by opening a second production facility (a midwest location to complement its current facility in California).

Key Points: 
  • With this funding, PawCo will scale its operations by opening a second production facility (a midwest location to complement its current facility in California).
  • Additionally, the brand will further invest in growth, research and development, new recipes and marketing tactics to drive awareness for the plant-based pet food category.
  • PawCo offers a plant-based meat alternative that provides all the essential vitamins, minerals, and amino acids dogs need to thrive, without sacrificing taste and flavor.
  • To learn more about PawCo, please visit mypawco.com .

New Two-Year Results Show Sustained Improvement in Chronic Rhinitis Symptoms Following a Single Procedure with Aerin Medical’s RhinAer®

Retrieved on: 
Thursday, February 29, 2024
Health, Medical Devices, Health Technology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Ear, Multimedia, Randomized controlled trial, Sneeze, Inflammation, Nose, Physician, Quality of life, Itch, Congestion, ENT, Patient, Otorhinolaryngology, Allergy, Cough, Pharmaceutical industry

These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.

Key Points: 
  • These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.
  • These findings build on the previously published results of two separate studies that also demonstrated significant, sustained improvement with RhinAer treatment.1,2
    This press release features multimedia.
  • More than 87% of patients responded to treatment and patients showed sustained improvement in chronic rhinitis symptoms at two years.
  • Chronic rhinitis, when symptoms last more than four consecutive weeks, can be challenging to treat and may significantly lower a person’s quality of life.

AllerVie Health Names Tae Kim as New CEO

Retrieved on: 
Wednesday, February 28, 2024
General Health, Other Health, Hospitals, Health, Practice Management, Allergy, Acquisition, Army aviation, Multimedia, AI, Physician, Mentorship, Growth, Asthma, Martin, Shield AI, Sale, Army, Patient, Goldman Sachs, Nursing

Today, AllerVie Health , a national network of allergy clinics, announced Tae Kim will be the company's new chief executive officer.

Key Points: 
  • Today, AllerVie Health , a national network of allergy clinics, announced Tae Kim will be the company's new chief executive officer.
  • "I've had the privilege of working with and mentoring Tae since we partnered for the incredibly successful sale of Epic Health Services in 2016.
  • Prior to joining AllerVie, Kim served as the chief operating officer and chief financial officer at Martin UAV, an aerospace technology company.
  • AllerVie will continue to fulfill its mission by crafting and pioneering healthcare solutions that benefit its patients, physicians, and team members.

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on: 
Tuesday, February 20, 2024
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Annual general meeting, Convention center, Allergy, Asthma, AAAAI, University, Therapy, Internal medicine, Level 2, American Academy, Pharmaceutical industry

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST.
  • Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present a poster titled, “Updated Results from a Phase 1a Trial of STAR-0215 for Hereditary Angioedema” at 3:15pm EST in the Convention Center, Level 2, Hall D, poster number 032.

RedBox Rx Releases New Study That Finds Nearly 3 Out of 4 Americans Struggled with Mental Health

Retrieved on: 
Tuesday, February 20, 2024
Women, Generation Z, Seniors, Retail, Teens, Pharmaceutical, Men, Research, Telemedicine, Virtual Medicine, Mental Health, Online Retail, Consumer, Science, General Health, Millennials, Health, Supermarket, Specialty, Redbox, Pharmacy, Anxiety, Mental health, Morning Consult, Multimedia, Intelligence, Education, Consultant, Loneliness, Skin, Allergy, Stage fright, Patient, Rx, ADHD, Insomnia, Failure, Insurance, Depression, Nursing

The study was commissioned by RedBox Rx, a telehealth and online pharmacy provider that specializes in mental health treatment, and conducted by Morning Consult, a global intelligence company.

Key Points: 
  • The study was commissioned by RedBox Rx, a telehealth and online pharmacy provider that specializes in mental health treatment, and conducted by Morning Consult, a global intelligence company.
  • “Mental health remains a struggle for many Americans,” said Dr. Daniel Fick, RedBox Rx’s chief medical officer.
  • Those suffering from worsening mental health were more likely to have experienced the following:
    The study also indicated that mental health challenges varied among age groups.
  • RedBox Rx offers treatment plans for men’s health , women’s health , hair and skin , mental health , allergies and more.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Retrieved on: 
Friday, March 8, 2024
Gastroesophageal reflux disease, Research, Heartburn, Blood, Diet, Cholesterol, Dietary supplement, Obesity, Dizziness, Pancreatitis, Vomiting, Health care, History, Thyroid cancer, Fatigue, Hypoglycemia, Acute kidney injury, Depression, Patient, Kidney disease, Abdominal distension, Burping, Cosmetics, Cardiovascular disease, Suicide, Weight, Stroke, Nausea, Diabetic retinopathy, Pancreas, Insulin, Blood pressure, Multimedia, Overweight, Diarrhea, Novo Nordisk, Vaccine, Safety, Heated tobacco product, Indigestion, Heart, Human services, Priority review, Division, Headache, Inflammation, FDA, Food, Weight loss, Thought, Heart rate, Gallstone, Risk, Animal, Allergy, Constipation, Death, Flatulence, Public

"This patient population has a higher risk of cardiovascular death, heart attack and stroke.

Key Points: 
  • "This patient population has a higher risk of cardiovascular death, heart attack and stroke.
  • Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
  • Obesity or overweight affect approximately 70% of American adults.
  • Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.

Smart Packaging Innovation Pushes Ophthalmic Market to $527.8 Million by 2034

Retrieved on: 
Thursday, March 7, 2024
Ophthalmology, Corning, Eye, Infection, Research, Medicine, OTC, Indian stock exchange, Ageing, Growth, Projection, Allergy, Prevalence, Safety, Glass, Macular degeneration, Gel, Health, Patient, FMI, Knowledge, Sample, Glaucoma

Ophthalmic Drug Packaging Market Overview:

Key Points: 
  • Ophthalmic Drug Packaging Market Overview:
    The global ophthalmic drug packaging market is expected to grow steadily, reaching an estimated value of US$527.8 million by 2034, according to Future Market Insights' recent study.
  • One of the challenges in the global ophthalmic drug packaging market is assuring compatibility between novel packaging materials and sensitive ophthalmic medicines.
  • The global ophthalmic drug packaging market size reached US$ 222.3 million in 2019.
  • Future Market Insights offers an unbiased analysis of the ophthalmic drug packaging market, providing historical data for 2019 to 2022 and forecast statistics from 2023 to 2033.

Smart Packaging Innovation Pushes Ophthalmic Market to $527.8 Million by 2034

Retrieved on: 
Thursday, March 7, 2024
Ophthalmology, Corning, Eye, Infection, Research, Medicine, OTC, Indian stock exchange, Ageing, Growth, Projection, Allergy, Prevalence, Safety, Glass, Macular degeneration, Gel, Health, Patient, FMI, Knowledge, Sample, Glaucoma

Ophthalmic Drug Packaging Market Overview:

Key Points: 
  • Ophthalmic Drug Packaging Market Overview:
    The global ophthalmic drug packaging market is expected to grow steadily, reaching an estimated value of US$527.8 million by 2034, according to Future Market Insights' recent study.
  • One of the challenges in the global ophthalmic drug packaging market is assuring compatibility between novel packaging materials and sensitive ophthalmic medicines.
  • The global ophthalmic drug packaging market size reached US$ 222.3 million in 2019.
  • Future Market Insights offers an unbiased analysis of the ophthalmic drug packaging market, providing historical data for 2019 to 2022 and forecast statistics from 2023 to 2033.

Defense Blends Icon Age Defense Face Moisturizer Wins The HisHealthMag 2024 Award for the Cleanest, Most Effective Anti-Aging Men's Moisturizer

Retrieved on: 
Thursday, March 7, 2024
Q10, Dry, Ageing, Defense, Skin, Hyperpigmentation, Hyaluronic acid, Allergy, Oil, Antioxidant, Irritation, Cosmetics

NEW YORK, March 7, 2024 /PRNewswire/ -- In the emerging market of men's skincare products, Defense Blends has garnered attention as an effective option for men seeking to combat visible signs of aging. Recognizing the brand's excellence, HisHealthMag has named Defense Blends Icon Age Defense Face Moisturizer as the cleanest and most effective anti-aging men's moisturizer. [See full press release.]

Key Points: 
  • HisHealthMag has chosen Defense Blends Icon Age Defense Face Moisturizer as the cleanest, most effective anti-aging men's moisturizer, recognizing the product's excellence in men's skincare.
  • NEW YORK, March 7, 2024 /PRNewswire/ -- In the emerging market of men's skincare products, Defense Blends has garnered attention as an effective option for men seeking to combat visible signs of aging.
  • Recognizing the brand's excellence, HisHealthMag has named Defense Blends Icon Age Defense Face Moisturizer as the cleanest and most effective anti-aging men's moisturizer.
  • Their Icon Age Defense Face Moisturizer epitomizes the brand's commitment to gentle yet effective skincare.